Molecular Profile |
Indication/Tumor Type |
Response Type |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
KRAS mutant
|
lung adenocarcinoma
|
no benefit |
Salirasib
|
Phase II |
Actionable |
In a Phase II clinical trial, salirasib showed no benefit in KRAS-mutant lung adenocarcinoma patients (PMID: 21847063).
|
21847063
|
KRAS G13X
|
Advanced Solid Tumor
|
predicted - sensitive |
Salirasib
|
Phase I |
Actionable |
In a Phase I clinical trial, Salirasib was well tolerated in Japanese patients with advanced solid tumors (n=21), and while the median progression-free survival (PFS) in the study overall was 53 days, patients harboring mutations in codon G12 or G13 of Kras (n=4) had a median PFS of 227 days (PMID: 29992354).
|
29992354
|
Unknown unknown
|
Advanced Solid Tumor
|
not applicable |
Salirasib
|
Phase I |
Actionable |
In a Phase I clinical trial, Salirasib treatment was well tolerated in Japanese patients with advanced solid tumors (n=21) and resulted in a median progression-free survival of 53 days (PMID: 29992354).
|
29992354
|
KRAS G12X
|
Advanced Solid Tumor
|
predicted - sensitive |
Salirasib
|
Phase I |
Actionable |
In a Phase I clinical trial, Salirasib was well tolerated in Japanese patients with advanced solid tumors (n=21), and while the median progression-free survival (PFS) in the study overall was 53 days, patients harboring mutations in codon G12 or G13 of Kras (n=4) had a median PFS of 227 days (PMID: 29992354).
|
29992354
|